University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390, USA.
Nat Rev Nephrol. 2012 May;8(5):257-8. doi: 10.1038/nrneph.2012.62.
Aliskiren combined with other inhibitors of the renin–angiotensin system increases the risk of hyperkalemia. This risk does not translate into an increased incidence of acute kidney injury, suggest the results of a meta-analysis. However, further research is needed to fully evaluate the safety of combination therapy with aliskiren.
阿利吉仑与肾素-血管紧张素系统其他抑制剂联合使用会增加高钾血症的风险。一项荟萃分析结果表明,这种风险不会转化为急性肾损伤发生率的增加。然而,需要进一步的研究来全面评估阿利吉仑联合治疗的安全性。